Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis.
Nonalcoholic steatohepatitis (NASH) predicts incident diabetes independently of insulin resistance, adiposity and metabolic syndrome through unclear mechanisms. Dietary fat consumption and lipoperoxidative stress predispose to diabetes in the general population and to liver injury in NASH. Microsomal triglyceride transfer protein (MTP) polymorphism modulates lipoprotein metabolism in the general population and liver disease in NASH; a functional MTP polymorphism recently predicted incident diabetes independently of insulin resistance in the general population. We simultaneously assessed the impact of MTP polymorphism, diet, adipokines and lipoprotein metabolism, on glucose homeostasis in NASH. MTP -493G/T polymorphism, dietary habits, adipokines and postprandial triglyceride-rich lipoproteins, high-density lipoprotein cholesterol (HDL-C) and oxidized low-density lipoprotein (oxLDL) responses to an oral fat load, were cross-sectionally correlated to oral glucose tolerance test- and frequently sampled intravenous glucose tolerance test-derived Minimal Model indexes of glucose homeostasis in 40 nondiabetic normolipidemic patients with NASH and 40 age-,sex- and body mass index-matched healthy controls. Despite comparable insulin resistance, fasting lipids, adipokines and dietary habits, MTP GG genotype had significantly more severe beta-cell dysfunction; higher plasma Tg, FFA, intestinal and hepatic very low-density lipoprotein 1 subfractions and oxLDL responses and deeper HDL-C fall than GT/TT carriers in patients and controls. Postprandial HDL-C and oxLDL responses independently predicted beta-cell dysfunction and mediated the effect of MTP polymorphism on beta-cell function. In nondiabetic normolipidemic NASH, MTP -493G/T polymorphism modulates beta-cell function, an effect mediated by postprandial HDL-C and oxLDL metabolism. The impact of this polymorphism on the risk of diabetes and the efficacy of lipid-lowering therapies in restoring beta-cell function in NASH, even with normal fasting lipid values, warrant further investigation.
Musso
Giovanni
G
Gradenigo Hospital, Turin, Italy. giovanni_musso@yahoo.it
Gambino
Roberto
R
Cassader
Maurizio
M
D000328:Adult; D002352:Carrier Proteins / Q000235:genetics*; D008076:Cholesterol, HDL; D003920:Diabetes Mellitus / Q000209:etiology*; D004041:Dietary Fats / Q000378:metabolism; D005234:Fatty Liver / Q000150:complications* / Q000378:metabolism; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D050417:Insulin-Secreting Cells / Q000502:physiology*; D008074:Lipoproteins / Q000378:metabolism*; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D019518:Postprandial Period; D012306:Risk
D002352:Carrier Proteins; D008076:Cholesterol, HDL; D004041:Dietary Fats; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; C106092:microsomal triglyceride transfer protein; C099252:oxidized low density lipoprotein